StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Agios Pharmaceuticals's pe ratio was 3.9× on Oct 31, 2025, against 0.8× a year earlier. Over the last 2 years it ranged from 0.8× to 5.2×, with a median of 2.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Oct 31, 20253.9×+1.0
2024Dec 31, 20242.9×+2.1
2022Apr 29, 20220.8×−0.6
2021Dec 31, 20211.5×–

More Agios Pharmaceuticals figures

See a number that looks wrong?